Perrigo Company plc Income Taxes Paid
Perrigo Company plc (PRGO) reported Income Taxes Paid of $98.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaid · last filed 2026-02-26
- Perrigo Company plc income taxes paid for the quarter ending 2016-12-31 was $22.90M, a 66.32% decline year-over-year.
- Perrigo Company plc income taxes paid for the quarter ending 2016-10-01 was $78.60M, a 296.97% increase year-over-year.
- Perrigo Company plc income taxes paid for the quarter ending 2016-07-02 was $3.50M, a 80.56% decline year-over-year.
- Perrigo Company plc income taxes paid for the quarter ending 2016-04-02 was $34.50M, a 62.58% decline year-over-year.
- Perrigo Company plc income taxes paid for fiscal 2025 was $98.90M, a 36.48% decline from fiscal 2024.
- Perrigo Company plc income taxes paid for fiscal 2024 was $155.70M, a 44.84% increase from fiscal 2023.
- Perrigo Company plc income taxes paid for fiscal 2023 was $107.50M, a 7.29% increase from fiscal 2022.
- Perrigo Company plc income taxes paid for fiscal 2022 was $100.20M, a 77.63% decline from fiscal 2021.
| Period end | Income Taxes Paid 3 month | Income Taxes Paid 6 month | Income Taxes Paid 9 month | Income Taxes Paid 12 month |
|---|---|---|---|---|
| 2025-12-31 | $98.90M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $155.70M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $107.50M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $100.20M 10-K · filed 2025-02-28 | |||
| 2021-12-31 | $448.00M 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $81.20M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $136.20M 10-K · filed 2022-03-01 | |||
| 2018-12-31 | $144.20M 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $186.90M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $22.90M derived: 10-K 12 month − 10-Q/A 9 month · filed 2019-02-27 | $101.50M derived: sum of 2 quarters · filed 2019-02-27 | $105.00M derived: sum of 3 quarters · filed 2019-02-27 | $139.50M 10-K · filed 2019-02-27 |
| 2016-10-01 | $78.60M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-05-23 | $82.10M derived: sum of 2 quarters · filed 2017-05-23 | $116.60M 10-Q/A · filed 2017-05-23 | $184.60M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-07-02 | $3.50M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-05-22 | $38.00M 10-Q/A · filed 2017-05-22 | $106.00M derived: sum of 3 quarters · filed 2018-03-01 | $125.80M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-04-02 | $34.50M 10-Q/A · filed 2017-05-22 | $102.50M derived: sum of 2 quarters · filed 2018-03-01 | $122.30M derived: sum of 3 quarters · filed 2018-03-01 | $140.30M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $68.00M derived: 10-K 6 month − 10-Q 3 month · filed 2018-03-01 | $87.80M 10-K · filed 2018-03-01 | $105.80M derived: sum of 3 quarters · filed 2018-03-01 | $198.00M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-09-26 | $19.80M 10-Q · filed 2015-11-02 | $37.80M derived: sum of 2 quarters · filed 2017-05-22 | $130.00M 10-Q/A · filed 2017-05-23 | $139.90M derived: sum of 4 quarters · filed 2017-05-22 |
| 2015-06-27 | $18.00M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-05-22 | $110.20M 10-Q/A · filed 2017-05-22 | $120.10M derived: sum of 3 quarters · filed 2017-05-22 | $131.00M 10-K · filed 2018-03-01 |
| 2015-03-28 | $92.20M 10-Q/A · filed 2017-05-22 | $102.10M derived: sum of 2 quarters · filed 2017-05-22 | $113.00M 10-Q · filed 2015-04-29 | $122.90M derived: sum of 4 quarters · filed 2017-05-22 |
| 2014-12-27 | $9.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-05 | $20.80M 10-Q · filed 2015-02-05 | $30.70M derived: sum of 3 quarters · filed 2017-05-22 | $40.10M derived: sum of 4 quarters · filed 2017-05-22 |
| 2014-09-27 | $10.90M 10-Q · filed 2015-11-02 | $20.80M derived: sum of 2 quarters · filed 2017-05-22 | $30.20M derived: sum of 3 quarters · filed 2017-05-22 | $82.00M derived: sum of 4 quarters · filed 2017-05-22 |
| 2014-06-28 | $9.90M derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | $19.30M derived: sum of 2 quarters · filed 2017-05-22 | $71.10M derived: sum of 3 quarters · filed 2017-05-22 | $93.20M 10-K · filed 2017-05-22 |
| 2014-03-29 | $9.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-29 | $61.20M derived: sum of 2 quarters · filed 2015-04-29 | $83.30M 10-Q · filed 2015-04-29 | $123.00M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-28 | $51.80M derived: 10-Q 6 month − 8-K 3 month · filed 2015-02-05 | $73.90M 10-Q · filed 2015-02-05 | $113.60M derived: sum of 3 quarters · filed 2016-02-25 | $139.20M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-09-28 | $22.10M 8-K · filed 2014-11-20 | $61.80M derived: sum of 2 quarters · filed 2016-02-25 | $87.40M derived: sum of 3 quarters · filed 2016-02-25 | |
| 2013-06-29 | $39.70M derived: 10-KT 12 month − 10-Q 9 month · filed 2016-02-25 | $65.30M derived: sum of 2 quarters · filed 2016-02-25 | $133.20M 10-KT · filed 2016-02-25 | |
| 2013-03-30 | $25.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-07 | $93.50M 10-Q · filed 2014-05-07 | ||
| 2012-12-29 | $67.90M 10-Q · filed 2014-02-06 | |||
| 2012-06-30 | $82.30M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |